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Abstract
 Aims—Incretin-based antihyperglycemic therapies increase intestinal mucosal expansion and 
polyp growth in mouse models. We aimed to evaluate the effect of dipeptidyl peptidase-4 
inhibitors (DPP-4i) or glucagon-like peptide-1 receptor agonists (GLP-1ra) initiation on colorectal 
cancer incidence.
 Methods—We conducted a cohort study on US Medicare beneficiaries over age 66 from 
2007-2013 without prevalent cancer. We identified three active-comparator and new-user cohorts: 
DPP-4i versus thiazolidinediones (TZD), DPP-4i versus sulphonylureas (SU), and GLP-1ra versus 
long acting insulin (LAI). Follow-up started from six months post second prescription and ended 
six months after stopping (primary as-treated analysis). We estimated hazard ratios (HR) and 95% 
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confidence intervals (CI) for incident colorectal cancer adjusting for measured confounders using 
propensity score weighting.
 Results—The median duration of treatment ranged 0.7-0.9 years among DPP-4i cohorts. 
Based on 104 events among 39,334 DPP-4i and 63 events among 25,786 TZD initiators, there was 
no association between DPP-4i initiation and colorectal cancer (adjusted HR=1.17 (CI: 0.88, 
1.71)). There were 73 events among 27,047 DPP-4i and 266 events among 76,012 SU initiators 
with the adjusted HR: 0.98 (CI: 0.74, 1.30). We identified 5,600 GLP-1ra and 54,767 LAI 
initiators and the median duration of treatment was 0.8 and 1.2 years, respectively. The adjusted 
HR was 0.82 (CI: 0.42, 1.58) based on <11 events among GLP-1ra versus 276 events among LAI 
initiators.
 Conclusion—Although limited by the short duration of treatment, our analyses based on real 
world drug utilization patterns provide evidence of no short-term effect of incretin-based agents on 
colorectal cancer.
Keywords
comparative effectiveness research; Dipeptidyl peptidase-4 inhibitors; glucagon-like peptide-1 
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 Introduction
Incretin-based therapies, glucagon-like peptide-1 receptor agonists (GLP-1ra) and dipeptidyl 
peptidase-4 inhibitors (DPP-4i), are commonly used second line therapies in the 
management of type 2 diabetes mellitus (DM) [1]. GLP-1ra are injected peptides, analogues 
or natural mimetics of human GLP-1, which enhance glycemic control by promoting 
glucose-dependent insulin secretion, suppressing fasting glucagon secretion, regulating 
gastric emptying and reducing appetite [2]. DPP-4 is the enzyme which degrades GLP-1 and 
as well as other biologically active peptides. Thus, DPP-4i exert their antihyperglycemic 
action by inhibiting this enzyme increasing endogenous incretin hormones levels [3].
GLP-1ra were first introduced in the United States in 2005. Exenatide was the first in class 
followed by liraglutide in 2010 and albiglutide and dulaglutide in 2015 [4]. They have been 
recommended because of their powerful efficacy, lack of intrinsic hypoglycemia as an 
adverse effect and associated weight loss; however, market penetration has been limited 
related to nausea, the need for injection, high cost and concerns about safety, particularly 
with regards to cancer and pancreatitis [1]. DPP-4i were approved in 2006. Sitagliptin was 
the first in class, followed by saxagliptin (2008), linagliptin (2011) and alogliptin (2012) [5]. 
The DPP-4i have been recommended related to reasonable efficacy, but excellent tolerability 
without nausea, weight-gain or hypoglycemia. Furthermore, large-scale cardiovascular 
outcome trials have been completed demonstrating no substantial safety concerns, 
particularly with market-leading sitagliptin [6-8].
GLP-1 receptor signaling has been found in genetically predisposed mice to stimulate 
intestinal mucosal expansion, increased polyp number and growth. In mouse studies 
exenatide was observed to increase small intestinal growth over 14-16 weeks after treatment 
and stimulated growth factor expression in colon polyps [9]. Currently there are no 
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population-based studies, which report the effect of incretin-based agents on the colorectal 
cancer incidence.
 Methods
We registered the study protocol in the European Network of Centers for 
Pharmacoepidemiology and Pharmacovigilance (ENCePP) electronic register of studies. 
(http://www.encepp.eu/encepp/viewResource.htm?id=3411). Our study was approved by the 
University of North Carolina at Chapel Hill Institutional Review Board.
 Study design
We conducted an active comparator, new user cohort study in a 20% random sample of U.S. 
Medicare beneficiaries 2007-2013 [10,11]. We identified three pairs of second line 
antihyperglycemic treatment initiators, who are likely to have similar stages of diabetes 
mellitus progression: DPP-4i versus TZD, DPP-4i versus SU, and GLP-1ra versus LAI [12]. 
These antihyperglycemic initiators were identified after requiring a twelve-month “drug 
free” period (six months for GLP-1ra versus LAI cohorts due to sample size) during which 
they could be treated with antihyperglycemic drugs other than the ones being compared 
(except for short-acting insulin for GLP-1ra versus LAI). All participants were required to 
have continuous enrollment in Medicare parts A, B, and D for twelve months (six months 
part D for GLP-1ra versus LAI) before the first prescription.
To increase the probability that patients actually took the dispensed medications, study 
participants were required to refill their prescription within the 30-day grace period (90 for 
injections) of the days’ supply of the first prescription. The date of the second prescription 
was defined as the baseline. Patients with any prevalent cancer related diagnosis or 
procedure codes (except for non-melanoma skin cancer: see Online Resource Appendix 
Table S1) during the 12-month period prior to the first prescription and between the first and 
the second prescriptions were excluded. [13].
 Outcome
The primary outcome of interest was colorectal cancer defined as at least two ICD-9 CM 
diagnosis codes of 153.X or 154.0 or 154.1 within two months. We required a second 
diagnosis code within two months after the first code to minimize the problem of rule-out 
diagnosis codes submitted as a part of surveillance and to maximize specificity [14]. We also 
included carcinoma-in-situ (230.3 and 230.4) and colorectal polyps or adenomas (45.42 and 
48.36) in our outcome definition as secondary analyses.
 Follow up and analyses
For our primary analysis we assumed a six-month lag period following second prescription 
to allow for an induction and latent period (delayed effect of the drug on cancer and 
preclinical phase) and excluded patients with incident colorectal cancer during this period 
[15]. We followed the remaining patients until switching, stopping or augmenting the drug 
(plus six-month lag time to allow for a latent period), the incidence of the outcome, any 
cancer (except non-melanoma skin cancer), all-cause mortality, end of enrollment in 
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Medicare Parts A and B, or December 31, 2013, whichever came first. We also performed an 
analysis in which patients were not censored when they stopped/switched/augmented 
therapy (first treatment carried forward).
 Confounding control
Our first line of confounding control was by design comparing pairs of initiators of 
treatments recommended for similar stages of progression of type 2 diabetes [12,16]. 
Potential remaining confounders were assessed before the first drug prescription date. We 
estimated separate propensity scores (PS) for each treatment pair predicting the probability 
of initiating incretins versus the comparator based on potential confounders using 
multivariable logistic regression [17,18]. To implement confounding control, we then 
assigned a weight of 1 to patients in the incretin cohorts and a weight of the propensity odds 
(PS/(1-PS)) to active comparators (TZD, SU or LAI) [19]. This weighting allows us to 
estimate the unconfounded treatment effect in a population defined by the covariate 
distribution of patients initiating incretin drugs (assuming no unmeasured confounding). We 
then fitted PS weighted Cox proportional hazards models with a robust variance estimator 
and weighted Kaplan-Meier survival curves to estimate the effect of initiation of incretins on 
the time to colorectal cancer. We ran separate Cox models stratified by the duration of 
treatment to assess the estimates over time.
 Assessment of potential bias
It is possible that patients initiating incretins are more likely to undergo diagnostic or 
screening procedures leading to earlier diagnosis of preclinical cancer, which could bias our 
results [20-22]. We checked for this potential differential detection by comparing the 
probability of having a colonoscopy in a year prior to and six months after the baseline 
prescription between our cohort pairs. We also excluded varying small proportions of 
patients in both tails of the PS including patients treated contrary to prediction (i.e., patients 
initiated on incretin drugs with the lowest PSs and patients treated with the comparator with 
the highest PSs) since it is plausible that some unmeasured characteristic made their 
physicians “override” the predicted treatment decision, which can lead to unmeasured 
confounding [23]. We varied the lag period prior to the start of follow up from six (primary 
analysis) to zero, twelve and twenty-four months to check the robustness of our 
assumptions. Other sensitivity analyses varying the censoring patterns are presented in 
Online Resource Appendix Tables S10 and S11.
 Results
We present baseline characteristics of the patients initiating DPP-4i, TZDs, and SUs in Table 
1. Compared with TZD initiators, DPP-4i initiators were slightly older, less likely to be men 
and more likely to be white. DPP-4i initiators were more likely to have major comorbidities 
and use statins, diuretics, angiotensin receptor blockers and beta blockers than TZD 
initiators. Among the DPP-4i (different from the above DPP-4i initiators) and SU initiators, 
DPP-4i initiators were less likely to be men, and had a higher prevalence of diabetic 
neuropathy, retinopathy, nephropathy, hypertension, and connective tissue disorders than SU 
initiators.
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We present baseline characteristics of the patients initiating GLP-1ra and LAI in Table 2. 
GLP-1ra initiators were younger and generally healthier than LAI initiators with fewer 
major comorbidities. Both incretins (DPP-4i in both cohort pairs and GLP-1ra) were more 
likely to be on metformin, use preventive services such as lipid testing and flu vaccination, 
less likely to have hospital admissions and more likely to have outpatient visits. The 
magnitude and direction of the association of each covariate with the treatment choice 
between GLP-1ra and LAI as estimated in the PS model is presented in PS model 
parameters column in Table 2. Covariate differences between our cohort pairs were removed 
after the propensity score weighting. One thing of note is that both incretins were more 
likely to be prescribed after 2010 than comparators, and this trend was most pronounced for 
DPP-4i versus TZD.
In Table 3, we present the number of events, the duration of treatment, the crude and 
adjusted (weighted) hazard ratios with their 95% confidence intervals for the various cohorts 
and comparisons. For the primary as treated analyses, there were 104 colorectal cancer 
events among 39,334 DPP-4i initiators and 63 among 25,786 TZD initiators and the fully 
adjusted HR was 1.17 (95% CI: 0.88, 1.71). For the DPP4i and SU comparison, there were 
73 colorectal cancer events among 27,047 DPP-4i initiators and 266 events among 76,012 
SU initiators. The fully adjusted HR was 0.98 (95% CI: 0.74, 1.30). The number of 
colorectal cancer events in 5,600 GLP-1ra initiators was less than 11, the minimum cell size 
that our data use agreement with CMS allows us to publish. The fully adjusted HR for 
GLP-1ra initiators versus LAI initiators was 0.82 (95% CI: 0.42, 1.58). We present weighted 
Kaplan-Meier plots for all treatment comparisons in Figure 1. The median duration of 
treatment ranges from 0.7-1.2 years for as treated analyses and 2.0-3.3 years for first 
treatment carried forward analyses (where treatment changes were uncensored), both of 
which revealed similar results (Table 3).
Our secondary analyses examined the composite outcome of invasive and in-situ colorectal 
cancer and cancer precursors (polyps/adenomas) (Online Resource Appendix Table S4). The 
fully adjusted HR was 0.95 (95% CI: 0.74, 1.23) for DPP-4i versus TZD and 1.08 (95% CI: 
0.90, 1.31) for DPP-4i versus SU. The fully adjusted HR for GLP-1ra versus LAI was 0.76 
(95% CI: 0.48, 1.23).
Changing our assumption about induction and latent periods (to allow for a delayed effect of 
antihyperglycemic drugs on colorectal cancer and a preclinical phase) to 0, 12 and 24 
months and stratifying the duration of treatment to assess the effects over time reveal 
consistent hazard ratios similar to our primary results (Online Resource Appendix Tables S5, 
S6, and Appendix Figures S1-S3). Assessment of potential detection bias also reveals 
similar proportions of colonoscopy between our cohorts. Other sensitivity analyses also 
suggested the robustness of our primary analyses (Online Resource Appendix Tables S7-
S12).
 Discussion
In this first population-based cohort study addressing the real world effects of incretins on 
colorectal cancer risk, we observed no short-term effect of DPP-4i and GLP-1a initiation on 
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the risk for colorectal cancer compared with initiation of alternative treatments indicated for 
similar stages of diabetes duration and severity. Like previous studies on antihyperglycemic 
treatments and cancer risk, our study was restricted to short-term use of incretins due to the 
real-world dynamics of antihyperglycemic treatments where only a small proportion of 
patients stay on the same drug class for prolonged periods of time [22]. This dynamic in 
treatments makes it very difficult to study long-term effects of treatments on cancer risk but 
also limits any potential public health impact on cancer risk.
To allow for some delay in the effect of the drug on late stage carcinogenesis [15], we 
allowed a six-month lag period before follow up and after censoring for treatment changes. 
Varying this lag period did not substantially change our results. Findings from first treatment 
carried forward analyses, which do not suffer from potential selection bias and provide a 
longer follow up time, also revealed similar estimates to our primary as treated analyses, 
suggesting that censoring of study participants due to drug changes is not informative with 
respect to colorectal cancer incidence.
A randomized controlled trial with three year follow up data on the sitagliptin versus 
placebo revealed similar finding to ours with the 0.3% colon cancer risk among sitagliptin 
initiators (21 cases among 7332 initiators) versus 0.5% risk among placebo (34 cases among 
7339 initiators), which though numerically slightly protective, was not statistically or 
clinically significant over a similar period of duration of treatment [6].
The major strength of our study is the utilization of the active comparator new user cohort 
study design, which restricts the study population to initiators of therapies with similar 
indication [12,24]. By selecting guideline recommended active comparator drugs we tried to 
minimize unmeasured confounding by indication and frailty [12]. While we cannot precisely 
measure neither the indication nor frailty, we implicitly control for these by selecting an 
active comparator drug class that is a clinical alternative for the same degree of disease 
progression as the treatment of interest. This implicit control by study design is very 
different from the “usual” control for a covariate during the analysis phase because it does 
not rely on a good measure of the indication or frailty.
As a result of our study design, the distribution of most measured risk factors for colorectal 
cancer was similar between DPP-4i initiators and TZD/SU cohorts even before adjustment 
using propensity scores. GLP-1ra initiators on the other hand represented a generally 
healthier and younger group of new users more likely to undergo preventive health services 
compared to LAI initiators [25]. While LAI is not a perfect active comparator, it has the 
advantage of being an injectable drug, similar to GLP-1ra. After propensity score weighting 
these differences were removed and the HR for the GLP-1ra versus LAI increased 
substantially. Most of this confounding was due to the health care utilization, which was 
strongly related to the risk of colorectal cancer diagnosis in our data.
Our study has limitations. Since drug utilization was assessed from pharmacy claims data on 
dispensed prescriptions, it is possible that patients did not actually initiate the drugs. We 
attempted to minimize this problem by requiring a second prescription of the same drug 
class before entering the cohorts. The median duration between the first and second scripts 
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was 30 days for DPP-4i cohorts (44 days for GLP-1ra cohort) and we lost approximately 
30% of each of our cohort pairs due to this requirement. Yet, the proportion of patients 
excluded was similar between incretins and their comparators, which minimizes the chance 
of selection bias (Online Resource Appendix Table S13).
While our study represents the real world pattern of drug utilization, our major limitation is 
the short duration of treatment and thus our findings should be interpreted cautiously. We 
observed consistent hazard ratios even 2 years after initiation but both the number of long-
term users and events were small. To minimize the limitation due to short duration of 
treatment, we looked at the effect of anti-hyperglycemic drugs initiation on the colorectal 
cancer precursors (polyps, adenomas and in situ cases) and results were similar to our 
primary analyses. We could not distinguish between polyps and adenoma cases due to the 
absence of separate billing codes in the claims data. The small number of events in our study 
especially among the GLP-1ra initiators is another limitation of our study. Many GLP-1ra 
initiators were previously on short and long acting insulin and thus were excluded from our 
study. This exclusion is, however, necessary to avoid comparing patients not doing well on 
the established treatment, most likely to be switched to the newest treatment on the market 
[24-27].
A final limitation of our study is that we could not adequately control for smoking, alcohol 
consumption, and body mass index (BMI), all risk factors for colorectal cancer [28-33]. We 
need to point out that while many of these are related to diabetes control and would likely 
confound any comparison of treated with untreated patients, our active comparator new user 
design limits confounding by these variables to the extent that these would influence the 
choice between two guideline recommended treatment alternatives. In addition, we adjusted 
chronic obstructive pulmonary disease as a proxy for smoking and major comorbid 
conditions related to obesity to partially account for confounding by these unmeasured 
factors [34].
In summary, we found evidence for no effect of real world patterns of treatment with 
incretin-based antihyperglycemic drugs (DPP-4i and GLP-1ra) on the short-term risk for 
colorectal cancer. Although our study is limited by a short median duration of treatment, our 
findings currently offer the best available evidence based on real world patterns of these 
treatments and thus should help clinicians make decisions about the relative benefit harm 
balance of these treatments.
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Fig 1. 
Propensity score weighted Kaplan-Meier plots of time to colorectal cancer between 
dipeptidyl peptidase-4 inhibitors (DPP-4i) versus thiazolidinediones (TZD) or 
sulphonylureas (SU) initiators, and glucagon-like peptide-1 receptor agonists (GLP-1ra) 
versus long acting insulin (LAI) initiators from 2007-2013 Medicare dataa
a
 Initiation or new use defined as dispensing at least 2 prescriptions within 30 days (90 days 
for GLP-1ra) after the days’ supply of the first prescription, after 12 months drug free period 
(6 months for GLP-1ra). Primary as treated analyses with 6 months lag period, in which 
follow-up started from 6 months after the date of the second prescription until the event or 
the earliest of any non-colorectal incident cancer (except non-melanoma skin cancer), 
discontinuation, switching or augmentation with the comparator drug, death, end of 
enrollment or Dec 31st, 2013. Propensity score weighting is accomplished by standardized 
morbidity ratio weighting in which a weight of 1 given to DPP-4i or GLP-1ra users and the 
propensity odds to TZD, SU or LAI users. This weighting balances the covariate 
distributions between comparator cohorts at baseline, controlling for measured confounders 
in Tables 1 and 2.
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Table 2
Distribution of selected baseline characteristics in initiators of glucagon-like peptide-1 receptor agonists 
(GLP-1ra) versus long acting insulin (LAI) initiatorsa
GLP-1ra LAI PS model
parametersb
SMR
weighted
LAI d
N
6,594
% N
63,909
% OR c 95% CI %
Age (years), mean
(S.D.)
71.8 (5.0) 74.5 (7.7) 71.8 (1.7)
66 - 70 3,264 49.5 25,168 39.4 1.00 (reference) 49.5
71 - 75 1,990 30.2 14,125 22.1 0.80 (0.75, 0.86) 30.3
76 - 80 887 13.5 10,237 16.0 0.55 (0.51, 0.60) 13.4
81 - 85 326 4.9 7,580 11.9 0.33 (0.30, 0.38) 4.9
≥86 years 127 1.9 6,799 10.6 0.19 (0.15, 0.22) 1.9
Sex
Male 2,650 40.2 25,666 40.2 0.85 (0.81, 0.90) 40.3
Race
White 5,764 87.4 47,112 73.7 1.00 (reference) 87.5
Black 399 6.1 9,535 14.9 0.42 (0.37, 0.47) 6.0
Other races 431 6.5 7,262 11.4 0.42 (0.38, 0.47) 6.5
Year of initiation
2007 255 3.9 2,420 3.8 1.01 (0.87, 1.18) 3.9
2008 965 14.6 10,683 16.7 1.00 (reference) 14.5
2009 625 9.5 10,306 16.1 0.63 (0.57, 0.70) 9.4
2010 774 11.7 9,771 15.3 0.77 (0.70, 0.86) 11.6
2011 1,073 16.3 10,238 16.0 0.94 (0.85, 1.04) 16.3
2012 1,403 21.3 10,783 16.9 1.07 (0.97, 1.18) 21.2
2013 1,499 22.7 9,708 15.2 1.27 (1.15, 1.40) 23.1
Comorbid conditions e
Diabetic neuropathy 1,375 20.9 14,202 22.2 0.97 (0.91, 1.04) 20.8
Diabetic nephropathy 511 7.7 7,605 11.9 0.91 (0.81, 1.03) 7.7
Diabetic retinopathy 1,007 15.3 10,928 17.1 0.77 (0.71, 0.83) 15.3
Congestive heart failure 978 14.8 18,244 28.5 0.86 (0.79, 0.93) 14.8
Myocardial infarction 56 0.8 2,152 3.4 0.62 (0.47, 0.82) 0.9
Chronic obstructive pulmonary disease 1,019 15.5 14,543 22.8 0.90 (0.83, 0.98) 15.6
Chronic kidney disease 1,489 22.6 22,847 35.7 0.76 (0.70, 0.82) 22.4
Connective tissue disease 2,100 31.8 17,595 27.5 1.25 (1.17, 1.33) 32.1
Depression 875 13.3 11,072 17.3 0.91 (0.84, 0.99) 13.3
Co-medications f
Metformin 4,779 72.5 32,905 51.5 1.47 (1.38, 1.57) 73.0
Thiazolidinediones 2,020 30.6 13,708 21.4 1.40 (1.31, 1.49) 31.4
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GLP-1ra LAI PS model
parametersb
SMR
weighted
LAI d
N
6,594
% N
63,909
% OR c 95% CI %
Sulfonylureas 3,657 55.5 33,714 52.8 0.74 (0.69, 0.78) 56.5
Angiotensin converting
enzyme inhibitors
3,150 47.8 31,448 49.2 0.88 (0.82, 0.93) 47.6
Angiotensin receptor blockers 2,229 33.8 15,027 23.5 1.38 (1.29, 1.48) 34.2
Statins 4,758 72.2 39,629 62.0 1.15 (1.07, 1.22) 72.3
Loop diuretics 1,666 25.3 22,512 35.2 1.00 (0.94, 1.08) 25.3
Other diuretics 2,882 43.7 22,652 35.4 1.16 (1.09, 1.23) 43.9
Beta blockers 3,132 47.5 33,294 52.1 0.91 (0.85, 0.95) 47.5
Calcium channel
blockers
2,101 31.9 22,502 35.2 0.94 (0.89, 1.00) 31.9
Health service utilization e
Colonoscopy 666 10.1 4,555 7.1 1.15 (1.05, 1.27) 10.3
Fecal for Occult Blood 567 8.6 3,945 6.2 1.12 (1.01, 1.23) 8.7
Lipid tests
0 1,039 15.8 21,885 34.2 1.00 (reference) 15.6
1 1,874 28.4 18,059 28.3 1.43 (1.30, 1.56) 28.3
2 1,795 27.2 12,713 19.9 1.69 (1.54, 1.86) 27.3
>=3 1,886 28.6 11,252 17.6 1.92 (1.74,2.11) 28.9
Flu vaccination 3,654 55.4 27,962 43.8 1.18 (1.11, 1.25) 55.5
Hospital admissions
0 4,178 63.4 26,730 41.8 1.00 (reference) 63.7
1 967 14.7 9,605 15.0 0.82 (0.75, 0.88) 14.7
2 or 3 778 11.8 11,809 18.5 0.62 (0.57, 0.67) 11.6
4-6 421 6.4 8,208 12.8 0.57 (0.51, 0.64) 6.3
>6 250 3.8 7,557 11.8 0.43 (0.37, 0.49) 3.7
Outpatient visits
0 339 5.1 9,697 15.2 0.49 (0.41, 0.58) 5.1
1 241 3.7 4,787 7.5 0.69 (0.58, 0.81) 3.6
2 or 3 538 8.2 6,749 10.6 1.00 (reference) 8.0
4-6 1,281 19.4 11,028 17.3 1.21 (1.09, 1.36) 19.2
>6 4,195 63.6 31,648 49.5 1.55 (1.39, 1.72) 64.1
Emergency room visits
0 4,962 75.3 35,477 55.5 1.00 (reference) 75.5
1 1,042 15.8 13,151 20.6 0.67 (0.62, 0.72) 15.7
>=2 590 8.9 15,281 23.9 0.44 (0.40, 0.49) 8.9
PS, propensity scores; OR, odds ratio; CI, confidence intervals; SMR, standardized morbidity ratio (weight of 1 given to GLP-1ra users and PS/(1-
PS) to LAI users, where PS stands for propensity score); s.d., standard deviation.
a
Initiation or new use defined as dispensing at least 2 prescriptions within 90 days after the days’ supply of the first prescription, after 6 months 
drug free period.
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bAssociation between each covariate and the initiation of GLP-1ra versus initiation of LAI as estimated from the propensity score model; odds 
ratios from multivariable logistic regression model; odds ratios >1.0 indicate more likely to be initiated on GLP-1ra than LAI.
cAge is defined as the linear plus quadratic term in the propensity score estimation model but the odds ratios for individual age groups are 
displayed here for easy interpretation.
d
Pseudo-population of LAI initiators weighted to the distribution of covariates of the GLP-1ra initiators using the propensity score to balance 
covariates (and therefore control for confounding).
e
Measured in the 12 months before drug initiation (the date of the first prescription).
f
Measured in the 6 months before drug initiation (the date of the first prescription).
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